Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months. There were no changes in cross linked fibrinogen degradation products or Protein C for pre or postmenopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short (maximum 36 months) and careful long term follow-up is necessary to detect clinically significant morbidity.
Summary
Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months. There were no changes in cross linked fibrinogen degradation products or Protein C for pre or postmenopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short (maximum 36 months) and careful long term follow-up is necessary to detect clinically significant morbidity.
Tamoxifen is widely used as adjuvant therapy in early breast cancer and overview analysis of randomised tamoxifen trials has demonstrated a prolongation of the disease-free interval and an overall survival advantage for patients receiving tamoxifen (EBCTCG, 1992; MacDonald et al., 1991) . Although tamoxifen is well tolerated with a low level of acute side effects, the optimum duration of treatment is unclear and there has only been limited data on long term side-effects (Powles et al., 1989; . Tamoxifen has both oestrogen agonist and antagonist properties which are organ and species specific, however, concern has been raised about oestrogen antagonist activity and long term adverse effects, for example on coagulation, lipid profile and cardiovascular pathology (Fox et al., 1981) . A number of anecdotal reports have suggested that tamoxifen therapy is associated with an increased risk of thromboembolic events in patients with advanced breast cancer (Lipton et al., 1984; Nevasaari et al., 1978; Hendrick & Subramanian 1980; Dahan et al., 1985) , however it is difficult to evaluate the contribution of tamoxifen to thrombosis in these patients because of the generally increased risk of thrombosis in cancer patients per se. For patients receiving tamoxifen as adjuvant therapy, the position is even less clear. The frequency of arterial or venous thrombosis has been reported to be 5.4% among patients who received adjuvant therapy compared with 1.6% in patients on observation in a retrospective review of 2,673 patients (Saphner et al., 1991) . The risk of thrombosis was highest for those patients receiving tamoxifen together with chemotherapy (Saphner et al., 1991) but tamoxifen as monotherapy was only associated with a marginal, if any, increase in thromboembolic events (Saphner et al., 1991; Fornander et al., 1991) and indeed it has been suggested that adjuvant tamoxifen may have a beneficial effect on thrombosis with a reduction in cardiovascular deaths (EBCTCG, 1992; MacDonald et al., 1991) .
We have investigated the effects of tamoxifen on coagulation parameters in normal healthy women who had been entered into a double-blind placebo controlled trial of tamoxifen as a chemopreventative agent in breast cancer (Powles et al., 1989; (EBCTCG, 1992; MacDonald et al., 1991) . Antithrombin III, which inhibits thrombin and other activated clotting factors, and Protein C and Protein S which are important natural inhibitors of coagulation (Esmon, 1987) were also assayed as deficiencies of these factors may lead to a hypercoaguable state and increased risk of thromboembolic events.
Patients, materials and methods
Normal healthy pre and postmenopausal women with a positive maternal history of breast cancer were enrolled in a double-blind placebo controlled pilot trial investigating the use of tamoxifen as a chemopreventative agent in breast cancer. The details of this trial haved been described previously (Powles et al., 1989; . Patients with a history of venous thrombosis or pulmonary embolism were excluded. Patients were prescribed 'tamoplac' and randomised in a double-blind fashion to receive tamoxifen 20mg/day or a placebo of identical appearance. A total of 515 patients had pretreatment blood samples taken for fibrinogen and antithrombin III assays and samples were repeated on treatment at 6 monthly intervals. A subset of 39 consecutive patients had pretreatment and on-treatment samples at 6 months for Protein C, Protein S and cross linked fibrin degradation products (XL-FDP).
Assays
Antithrombin III and Fibrinogen Antithrombin III (AT3) and plasma fibrinogen were assayed using functional photometric assays with the Cobus Mira and kits supplied by Boehringer Mannheim (Kit 759 376 for AT3 and Kit 524484 for fibrinogen). The methodology and principle for the AT3 assay is described by Becker et al. (Becker et al., 1984) and for fibrinogen by Hesse et al. (1981) . The normal range for AT3 was 20-291 U ml-' and for fibrinogen 140-450 mg dl-'. Protein C and Protein S Protein C and Protein S antigen (bound and free) were measured by enzyme linked immunosorbent assay) using peroxidase-conjugated rabbit anti-human Protein C and antihuman Protein S polyclonal antibodies. (Dako Ltd, High Wycombe, Buckinghamshire) (Avameas & Ternycke, 1971; Woodhams, 1988) .
The normal range for Protein C was 70-130 IU dl-' and for Protein S normal range was 70-130% pooled normal plasma.
Crosslinkedfibrin degradation products (XL-FDP) XL-FDP were measured by an immunoassay (Dimertest Enzyme Immunoassay supplied by Porton Cambridge Ltd, Maidenhead, Berkshire). The method employs a monoclonal antibody which recognises D-dimer and fragments containing the D-dimer epitope (Rylatt et al., 1988 ) (normal range <250 ng ml-').
Statistics
Results have been analysed for each treatment group as a whole and separately for pre and postmenopausal women and expressed as a percentage of the pretreatment value (± s.e.m.) for each group. The t-test was used to assess the significance of the change from the pretreatment value at each 6 monthly time point.
Results
For premenopausal women there was a reduction in plasma fibrinogen levels at 6 months on tamoxifen to 90% (± 7%) of pretreatment values (P<0.005) and this fall was sustained over the first year of follow-up (P<0.001) (Figure la here was no reduction in antithrombin 3 on treatment for premenopausal women (Figure 2b) , however there was a reduction in antithrombin 3 for postmenopausal women (Figure 2a ) to 96% ± 3% of pretreatment values at 12 months (P <0.05).
For premenopausal women there was no change in Protein S antigen or Protein C on treatment (Figure 3 ). For postmenopausal women there was an overall marginal reduction in Protein antigen to 90% of pretreatment levels at 6 months (P = 0.05) but no change in Protein C levels (Figure 4) . No subject had pretreatment. values of Protein C or Protein S antigen below 50% of the normal range. There were no significant changes in crosslinked FDP's for either pre or postmenopausal women on treatment with no value outside the normal range (250 mg ml-').
No thromboembolic events have been recorded so far in either arm.
Discussion
Tamoxifen has been implicated as a risk factor for thromboembolic disease however the only evidence for this has come from reports of patients with advanced disease in whom the presence of a hypercoaguable state may be multifactorial. This study has allowed evaluation of tamoxifen on coagulation factors in a placebo controlled trial in a population of normal women. Although the reduction in fibrinogen was no longer apparent after 12 months, this may be a reflection of low patient numbers at the later time points.
Fibrinogen, the plasma precursor of fibrin, is recognised as an important factor in the pathogenesis of arterial thrombotic disease and increased plasma levels are a major risk factor for ischaemic heart disease independent of the increased risk associated with high plasma cholesterol concentration (Becker et al., 1984; Lowe et al., 1991 Months after start of treatment (Lane et al., 1978) . Blood coagulation is controlled by two m pathways, antithrombin III and the protei (Esmon, 1987 (Esmon, 1987) . This occurs wher activated on the endothelial cell surface by ti to thrombomodulin. Protein S is an essential binds to Protein C for this reaction to be o0 1987). Inherited deficiency of either Protein C or S is associated with an increased incidence of deep vein thrombosis although the overall prevalence of deficiency of antithrombin III, Protein C or S in patients with recurrent thrombosis is only 8.3% (Tabernero, 1991; Heijboer, 1990 ). In our study there was no reduction in Protein C at 6 months and there was only a marginal reduction in Protein S in postmenopausal patients. Although congenital Protein S deficiency is a risk factor for venous thrombosis and has also been implicated as a risk factor for arterial thrombosis (Wiessel, 1991) (Sporrong, 1990) and support an oestrogen agonist action of tamoxifen.
Although these results for proteins C and S are reported after 6 months of treatment and longer follow-up may reveal further changes with time, our experience with fibrinogen and antithrombin III levels on tamoxifen suggests that the pattern seen at 6 months is sustained with time. This stable pattern is in keeping with the observation that tamoxifen metabolites in patients on long-term adjuvant tamoxifen are also stable with time (Langan-Fahey, 1991 (Saphner et al., 1991; Fornander et al., 1991) (Powles et al., 1989; . The findings in this )ostmenopausal study favour oestrogen agonist, rather than antagonist activity of tamoxifen and such changes may contribute to the ajor regulatory observed reduction in deaths from ischaemic heart disease in in C pathway women receiving adjuvant tamoxifen (EBCTCG, 1992 
